Ten pharmaceutical giants join US research initiative

February 4, 2014

Government researchers will collaborate with 10 large pharmaceutical companies on a $230 million initiative to speed development of new medications for major diseases, the US National Institutes of Health announced Tuesday.

The five-year initiative targets Alzheimer's Disease, , and lupus, and may be expanded to other ailments, the NIH said.

The goal is to pool resources among NIH and the companies, normally vigorous competitors, to enable analysis of large data sets to track disease progression and the effect of therapies.

Data and early-stage research will be shared and made publicly available, and companies are expected to compete on developing commercial drugs once research passes the preliminary phase.

"Currently, we are investing a great deal of money and time in avenues with high failure rates, while patients and their families wait," said NIH Director Francis Collins.

The challenge "is beyond the scope of any one of us and it's time to work together in new ways to increase our collective odds of success," Collins said.

Taking a drug from early discovery through government approval takes over a decade and 95 percent fail the test. That takes the cost of one success to more than $1 billion, NIH said.

The initiative will be overseen by steering committees led by representatives of NIG and the Food and Drug Administraiton, the private sector companies and patient advocacy groups.

"Our most critical health challenges require new, innovative ways to develop medicines and vaccines," said Rupert Vessey, a at Merck, which is joining the initiative.

"Collaborations such as this, that exchange data, share insights and generate knowledge will be important to unravelling the mysteries of the diseases that cause suffering for individuals and a burden to our society."

The other participating companies are: AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Pfizer, Sanofi and Takeda.

Explore further: Research slows on mental health drugs as investment shrinks

Related Stories

Research slows on mental health drugs as investment shrinks

November 26, 2013
Research into medications to treat mental health disorders, which affect almost a quarter of the US population, has slowed as major pharmaceutical companies cut back investment in this area, psychiatrists say.

Deciphering the DNA of Alzheimer's patients

December 4, 2013
(HealthDay)—Data that details every gene in the DNA of 410 people with Alzheimer's disease can now be studied by researchers, the U.S. National Institutes of Health announced this week.

US approves diabetes drug with new approach (Update)

January 8, 2014
The U.S. Food and Drug Administration on Wednesday approved a new diabetes drug from Bristol-Myers Squibb and AstraZeneca that uses a novel approach to reduce blood sugar.

Sanofi sues Eli Lilly for patent infringement

January 31, 2014
French pharmaceutical giant Sanofi has said it is suing US rival Eli Lilly in an American court for infringing four patents relating to its diabetes treatments.

NIH and Lilly to generate public resource of approved and investigational medicines

March 13, 2012
The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant ...

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.